Spyre Therapeutics (SYRE) Earnings Analysis
Spyre Therapeutics (SYRE) has no confirmed upcoming earnings date. Last quarter (2026-02-19) it missed with EPS -0.7 USD vs -0.66 USD est (-6.1%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -45.49.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SYRE next report earnings?
No confirmed upcoming earnings date is currently scheduled for SYRE. This page updates as the calendar is published.
SYRE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-19 | -0.7 USD | -0.66 USD | -6.1% | Miss |
| 2025-02-28 | -0.81 USD | -0.89 USD | +9% | Beat |
| 2024-11-07 | -1.36 USD | -0.8 USD | -70% | Miss |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
SYRE valuation and analyst view
| Trailing P/E | -45.49 |
|---|---|
| Trailing EPS | -0.51853 USD |
| Price / book | 51.16 |
| Dividend yield | 0.00% |
| Market cap | 6.03B |
| Analyst consensus | Buy (12 buy / 0 hold / 0 sell) |
| Avg price target | 113 USD |
Related research pages
Frequently asked questions
When is Spyre Therapeutics (SYRE)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for SYRE. This page updates as the calendar is published.
Did SYRE beat earnings last quarter?
In its 2026-02-19 report, SYRE posted EPS of -0.7 USD versus a -0.66 USD estimate — a miss of 6.1%.
What is SYRE's earnings track record?
Over the last 3 reported quarters with consensus data, SYRE beat estimates 1 times (33%).
What is SYRE's current P/E ratio and EPS?
SYRE trades at a trailing P/E of -45.49 on trailing EPS of -0.5185308269155746 USD.
What do analysts rate SYRE?
Analyst consensus is "Buy" across 12 ratings (0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 113 USD.